BRPI0607762B8 - análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto - Google Patents

análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto

Info

Publication number: BRPI0607762B8
Authority: BR; Brazil
Prior art keywords: glp; compound; pharmaceutical composition; analogues; composition containing
Prior art date: 2005-03-18

Application number

BRPI0607762A

Other languages

English (en)

Portuguese (pt)

Inventor

Zaragoza Dörwald Florencio

Stephensen Henrik

Lau Jesper

Madsen Kjeld

Bloch Paw

Kruse Hansen Thomas

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-18

Filing date

2006-03-20

Publication date

2021-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36821525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607762(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-03-20 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2010-03-23 Publication of BRPI0607762A2 publication Critical patent/BRPI0607762A2/pt

2019-05-07 Publication of BRPI0607762B1 publication Critical patent/BRPI0607762B1/pt

2021-05-25 Publication of BRPI0607762B8 publication Critical patent/BRPI0607762B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

BRPI0607762A 2005-03-18 2006-03-20 análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto BRPI0607762B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05102171.5		2005-03-18
EP05102171		2005-03-18
PCT/EP2006/060855 WO2006097537A2 (en)	2005-03-18	2006-03-20	Acylated glp-1 compounds

Publications (3)

Publication Number	Publication Date
BRPI0607762A2 BRPI0607762A2 (pt)	2010-03-23
BRPI0607762B1 BRPI0607762B1 (pt)	2019-05-07
BRPI0607762B8 true BRPI0607762B8 (pt)	2021-05-25

Family

ID=36821525

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0607762A BRPI0607762B8 (pt)	2005-03-18	2006-03-20	análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto
BR122019002626A BR122019002626A2 (2)	2005-03-18	2006-03-20

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR122019002626A BR122019002626A2 (2)	2005-03-18	2006-03-20

Country Status (25)

Country	Link
US (2)	US8129343B2 (2)
EP (2)	EP1863839B1 (2)
JP (3)	JP5209463B2 (2)
KR (1)	KR101205272B1 (2)
CN (3)	CN101133082B (2)
AT (1)	ATE476446T1 (2)
AU (1)	AU2006224536B9 (2)
BE (1)	BE2018C016I2 (2)
BR (2)	BRPI0607762B8 (2)
CA (1)	CA2601784C (2)
DE (1)	DE602006015928D1 (2)
DK (2)	DK1863839T3 (2)
ES (2)	ES2350051T3 (2)
FR (1)	FR18C1017I2 (2)
HU (2)	HUE028194T2 (2)
IL (1)	IL184051A (2)
MX (1)	MX2007011220A (2)
NL (1)	NL300936I2 (2)
NO (2)	NO337946B1 (2)
PL (2)	PL2322546T3 (2)
PT (2)	PT2322546E (2)
RU (1)	RU2434019C3 (2)
TW (2)	TWI362392B (2)
WO (1)	WO2006097537A2 (2)
ZA (1)	ZA200707261B (2)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658938B2 (en)	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
BR122019021416A2 (2) *	2003-09-19	2019-12-21
US8268791B2 (en) *	2004-08-25	2012-09-18	Aegis Therapeutics, Llc.	Alkylglycoside compositions for drug administration
US9895444B2 (en)	2004-08-25	2018-02-20	Aegis Therapeutics, Llc	Compositions for drug administration
US20060046962A1 (en)	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
US20140162965A1 (en)	2004-08-25	2014-06-12	Aegis Therapeutics, Inc.	Compositions for oral drug administration
WO2006037810A2 (en)	2004-10-07	2006-04-13	Novo Nordisk A/S	Protracted glp-1 compounds
US8030273B2 (en)	2004-10-07	2011-10-04	Novo Nordisk A/S	Protracted exendin-4 compounds
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
US8603972B2 (en)	2005-03-18	2013-12-10	Novo Nordisk A/S	Extended GLP-1 compounds
CN100374462C (zh) *	2005-11-21	2008-03-12	大连帝恩生物工程有限公司	截短胰高血糖素样肽1(sGLP-1)、制法及其应用
BRPI0710503A2 (pt)	2006-04-07	2011-08-16	Merrion Res Iii Ltd	uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US7998927B2 (en) *	2006-06-23	2011-08-16	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) *	2006-06-23	2008-09-16	Aegis Therapeutics, Inc.	Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) *	2006-06-23	2011-12-27	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) *	2006-06-23	2009-12-31	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) *	2006-06-23	2012-05-08	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en)	2006-06-23	2012-07-24	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
WO2009030771A1 (en) *	2007-09-05	2009-03-12	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) *	2007-09-05	2010-11-18	Novo Nordisk A/S	Truncated glp-1 derivaties and their therapeutical use
EP2190872B1 (en)	2007-09-05	2018-03-14	Novo Nordisk A/S	Glucagon-like peptide-1 derivatives and their pharmaceutical use
BRPI0820535B8 (pt)	2007-11-16	2021-05-25	Novo Nordisk As	composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
US20100317057A1 (en) *	2007-12-28	2010-12-16	Novo Nordisk A/S	Semi-recombinant preparation of glp-1 analogues
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
US20090258865A1 (en)	2008-03-28	2009-10-15	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
RU2517135C2 (ru)	2008-05-07	2014-05-27	Меррион Рисерч Iii Лимитед	Композиции пептидов и способы их получения
MX2011000847A (es) *	2008-08-06	2011-02-25	Novo Nordisk Healthcare Ag	Proteinas conjugadas con eficacia prolongada in vivo.
ES2561208T3 (es)	2008-09-12	2016-02-25	Novo Nordisk A/S	Método de acilación de un péptido o una proteína
US8440631B2 (en)	2008-12-22	2013-05-14	Aegis Therapeutics, Llc	Compositions for drug administration
MX2011007736A (es)	2009-01-22	2011-09-06	Novo Nordisk Healthcare Ag	Compuestos de hormona del crecimiento estables.
CN102361647B (zh)	2009-01-23	2018-02-16	诺沃-诺迪斯克有限公司	具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
JP2012529463A (ja) *	2009-06-11	2012-11-22	ノヴォノルディスクアー／エス	２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
AU2010272944B2 (en)	2009-07-13	2015-11-19	Zealand Pharma A/S	Acylated glucagon analogues
WO2011015649A1 (en)	2009-08-06	2011-02-10	Novo Nordisk Health Care Ag	Growth hormones with prolonged in-vivo efficacy
JP6006118B2 (ja)	2009-12-16	2016-10-12	ノヴォノルディスクアー／エス	Ｇｌｐ−１アナログ及び誘導体
MX338357B (es)	2010-01-22	2016-04-13	Novo Nordisk Healthcare Ag	Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr)	2010-01-22	2019-11-29	Novo Nordisk Healthcare Ag	Hormoni rasta sa produženom in-vivo efikasnošću
EP2539364A1 (en)	2010-02-26	2013-01-02	Novo Nordisk A/S	Peptides for treatment of obesity
EP2552951A1 (en)	2010-03-26	2013-02-06	Novo Nordisk A/S	Novel glucagon analogues
US9089484B2 (en)	2010-03-26	2015-07-28	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
AU2011247824B2 (en) *	2010-04-27	2014-02-13	Betta Pharmaceuticals Co., Ltd	Glucagon-like peptide-1 analogue and use thereof
JP5819946B2 (ja) *	2010-05-17	2015-11-24	ベータファーマシューティカルズカンパニーリミテッド	新規のグルカゴン様ペプチド類似体、組成物、および使用方法
WO2012016419A1 (zh) *	2010-08-06	2012-02-09	浙江贝达药业有限公司	Glp-1衍生物及其应用
JP6039569B2 (ja)	2010-11-09	2016-12-07	ノヴォノルディスクアー／エス	二重アシル化されたｇｌｐ−１誘導体
SI2651398T1 (en) *	2010-12-16	2018-04-30	Novo Nordisk A/S	SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
KR20140026354A (ko)	2011-01-07	2014-03-05	메리온 리서치 Ⅲ 리미티드	경구 투여용 철의 제약 조성물
EP2665470A1 (en)	2011-01-19	2013-11-27	Novo Nordisk A/S	Glp-1 particles and compositions
WO2012098187A1 (en)	2011-01-19	2012-07-26	Novo Nordisk A/S	Glp-1 compositions
RU2013145013A (ru) *	2011-03-28	2015-05-10	Ново Нордиск А/С	Новые аналоги глюкагона
JP5871905B2 (ja) *	2011-03-30	2016-03-01	ベータファーマシューティカルズカンパニーリミテッド	グルカゴン様ペプチド−１類似体およびその使用
PL2696687T3 (pl)	2011-04-12	2017-06-30	Novo Nordisk A/S	Pochodne podwójnie acylowanej GLP-1
KR102093463B1 (ko) *	2011-04-12	2020-03-26	노보 노르디스크 에이/에스	이중 아실화된 ｇｌｐ-1 유도체
ES2683902T3 (es)	2011-06-14	2018-09-28	Hale Biopharma Ventures, Llc	Administración de benzodiacepina
BR112014001274A2 (pt)	2011-07-18	2017-04-18	Arts Biologics As	composto de hormônio luteinizante, e, composição farmacêutica
JP6126097B2 (ja)	2011-09-06	2017-05-10	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体
AU2012311484B2 (en)	2011-09-23	2017-04-13	Novo Nordisk A/S	Novel glucagon analogues
CN110041399B (zh)	2011-12-29	2023-12-12	诺沃—诺迪斯克有限公司	包含非成蛋白质性的氨基酸的二肽
JP6411218B2 (ja)	2012-02-15	2018-10-24	ノヴォノルディスクアー／エス	骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
CN104203977A (zh)	2012-02-15	2014-12-10	诺和诺德A/S（股份有限公司）	结合肽聚糖识别蛋白1的抗体
HRP20181447T1 (hr)	2012-03-22	2018-11-02	Novo Nordisk A/S	Pripravci glp-1 peptida i njihova priprava
KR102266299B1 (ko) *	2012-03-22	2021-06-18	노보 노르디스크 에이/에스	Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
PT2827845T (pt)	2012-03-22	2019-03-29	Novo Nordisk As	Composições compreendendo um agente de entrega e sua preparação
ES2965469T3 (es)	2012-03-22	2024-04-15	Novo Nordisk As	Composiciones que comprenden un agente de suministro y preparación de estas
IN2014MN02304A (2)	2012-05-03	2015-08-07	Zealand Pharma As
CN104411322B (zh) *	2012-05-08	2017-05-24	诺和诺德股份有限公司	双酰化glp‑1衍生物
EP2846823B1 (en)	2012-05-08	2019-12-04	Novo Nordisk A/S	Double-acylated glp-1 derivatives
EP2851429B1 (en)	2012-05-18	2019-07-24	Adda Biotech Inc.	Protein and protein conjugate for diabetes treatment, and applications thereof
JP6517690B2 (ja) *	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
EP2866825B1 (en) *	2012-07-01	2020-04-08	Novo Nordisk A/S	Use of long-acting glp-1 peptides
IN2015DN00544A (2)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
WO2014060472A1 (en)	2012-10-17	2014-04-24	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
EP2986313B1 (en)	2013-04-18	2019-06-12	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
KR102272671B1 (ko)	2013-05-02	2021-07-06	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
JP6475233B2 (ja) *	2013-06-20	2019-02-27	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
EP3016975B1 (en)	2013-07-04	2019-01-16	Novo Nordisk A/S	Derivatives of glp-1 like peptides, and uses thereof
EP3033112B1 (en)	2013-08-15	2020-10-07	Novo Nordisk A/S	Glp-1 derivatives, and uses thereof
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
JP6822839B2 (ja)	2013-09-13	2021-01-27	ザ・スクリップス・リサーチ・インスティテュート	修飾された治療剤、及びその組成物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
US10626156B2 (en)	2013-12-06	2020-04-21	Jie Han	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
KR102455171B1 (ko)	2013-12-18	2022-10-14	더 스크립스 리서치 인스티튜트	변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
MX2016010599A (es)	2014-02-18	2016-11-18	Novo Nordisk As	Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
ES2741507T3 (es)	2014-04-07	2020-02-11	Novo Nordisk As	Compuestos de glp-1 acilados doblemente
WO2015169789A1 (en)	2014-05-07	2015-11-12	Novo Nordisk A/S	Treatment of diabetes type 1 using glp-1 and anti-il-21
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
EA037844B1 (ru)	2014-07-17	2021-05-27	Ново Нордиск А/С	Сайт-направленный мутагенез антител к trem-1
ES2685987T3 (es)	2014-09-05	2018-10-15	University Of Copenhagen	Análogos de péptidos gip
GR20140100479A (el) *	2014-09-23	2016-05-05	Novetide, Ltd.,	Συνθεση λιραγλουτιδης
ES2630106T3 (es)	2014-10-07	2017-08-18	Cyprumed Gmbh	Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
JP6730278B2 (ja) *	2014-11-27	2020-07-29	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en)	2014-12-17	2016-06-23	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
AR103246A1 (es)	2014-12-23	2017-04-26	Novo Nordiks As	Derivados de fgf21 y sus usos
US20180263915A1 (en) *	2015-01-29	2018-09-20	Novo Nordisk A/S	Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
JP7211704B2 (ja) *	2015-01-29	2023-01-24	ノヴォノルディスクアー／エス	Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
DK3283507T3 (da) *	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
CN107708667A (zh) *	2015-06-16	2018-02-16	太阳医药高级研发有限公司	长效利拉鲁肽组合物
WO2016205488A1 (en)	2015-06-17	2016-12-22	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
CN106554403B (zh) *	2015-09-25	2021-08-31	博瑞生物医药（苏州）股份有限公司	艾塞那肽修饰物及其用途
CN106554408A (zh) *	2015-09-30	2017-04-05	天津药物研究院有限公司	长效胰高血糖素样肽-1类似物二聚体及其应用
CN106554409B (zh) *	2015-09-30	2020-04-07	天津药物研究院有限公司	一种长效胰高血糖素样肽-1类似物及其应用
JP2018529749A (ja)	2015-10-07	2018-10-11	シプルメット・ゲーエムベーハー	ペプチド薬物を経口送達するための医薬製剤
CN106928343A (zh) *	2015-12-30	2017-07-07	深圳翰宇药业股份有限公司	索玛鲁肽的制备方法
US10946074B2 (en)	2016-03-03	2021-03-16	Novo Nordisk A/S	GLP-1 derivatives and uses thereof
CN107266557B (zh) *	2016-04-06	2020-04-07	天津药物研究院有限公司	一种聚乙二醇修饰的胰高血糖素样肽-1类似物
CA3022535A1 (en)	2016-04-28	2017-11-02	Novo Nordisk A/S	Semaglutide in cardiovascular conditions
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
WO2018078112A1 (en)	2016-10-27	2018-05-03	Aarhus Universitet	Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
ES2828526T3 (es)	2016-11-07	2021-05-26	Novo Nordisk As	Esteres activos DCHBS de compuestos PEG y sus usos
PE20210857A1 (es)	2016-12-16	2021-05-18	Novo Nordisk As	Composiciones farmaceuticas que contienen insulina
CN107033234B (zh) *	2017-01-03	2018-06-26	北京凯因科技股份有限公司	酰化的glp-1衍生物
MX2019010651A (es) *	2017-03-08	2020-01-13	Intarcia Therapeutics Inc	Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.
KR102743887B1 (ko)	2017-05-31	2024-12-19	유니버시티 오브 코펜하겐	장기-작용성 gip 펩타이드 유사체
TWI797133B (zh)	2017-06-09	2023-04-01	丹麥商諾佛儂迪克股份有限公司	用於經口投予的固體組成物
CN109248323B (zh) *	2017-07-14	2023-09-08	杭州先为达生物科技有限公司	酰化的glp-1衍生物
CA3068956A1 (en) *	2017-07-19	2019-01-24	Novo Nordisk A/S	Bifunctional compounds
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
CN111163795A (zh)	2017-09-10	2020-05-15	诺沃挪第克公司	用于治疗肥胖症的mic-1和glp-1
US11357861B2 (en)	2017-09-29	2022-06-14	Hanmi Pharm. Co., Ltd	Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
CA3078652A1 (en)	2017-10-12	2019-04-18	Novo Nordisk A/S	Semaglutide in medical therapy
CN107881187A (zh) *	2017-11-20	2018-04-06	珠海联邦制药股份有限公司	将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
EP3728304B1 (en) *	2017-12-21	2025-02-12	Bachem Holding AG	Solid phase synthesis of acylated peptides
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
WO2019157099A1 (en)	2018-02-06	2019-08-15	Aegis Therapeutics, Llc	Intranasal epinephrine formulations and methods for the treatment of disease
CN110294800B (zh) *	2018-03-22	2022-03-04	齐鲁制药有限公司	一种索玛鲁肽的制备方法
WO2019195126A1 (en)	2018-04-02	2019-10-10	Bristol-Myers Squibb Company	Anti-trem-1 antibodies and uses thereof
MX2020010505A (es)	2018-04-05	2021-01-15	Sun Pharmaceutical Ind Ltd	Analogos novedosos de glp-1.
WO2019193204A1 (en)	2018-04-06	2019-10-10	Cyprumed Gmbh	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
CN110386974B (zh) *	2018-04-19	2022-12-09	杭州先为达生物科技有限公司	Glp-1衍生物及其治疗用途
WO2019200594A1 (zh) *	2018-04-19	2019-10-24	杭州先为达生物科技有限公司	酰化的glp-1衍生物
US11633459B2 (en)	2018-05-04	2023-04-25	Novo Nordisk A/S	GIP derivatives and uses thereof
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
SG11202103137WA (en)	2018-10-26	2021-04-29	Novo Nordisk As	Stable semaglutide compositions and uses thereof
CN109180801B (zh) *	2018-11-01	2021-08-13	汉肽生物医药集团有限公司	一种合成索玛鲁肽的方法
SG11202105586YA (en)	2018-12-03	2021-06-29	Antag Therapeutics Aps	Modified gip peptide analogues
WO2020127476A1 (en)	2018-12-19	2020-06-25	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
ES2994462T3 (en)	2018-12-21	2025-01-24	Novo Nordisk As	Process of spray drying of glp-1 peptide
MA54807A (fr)	2019-01-24	2022-04-27	Novo Nordisk As	Compacteur à rouleaux et procédé de granulation à sec utilisant un compacteur à rouleaux
CA3128081A1 (en)	2019-02-12	2020-08-20	Ambrx, Inc.	Compositions containing, methods and uses of antibody-tlr agonist conjugates
JP7495420B2 (ja)	2019-02-20	2024-06-04	ノヴォノルディスクアー／エス	アミノアシル－ｔＲＮＡ合成酵素およびこの使用
WO2020180534A1 (en)	2019-03-01	2020-09-10	President And Fellows Of Harvard College	Methods and compositions for protein delivery
JP7549593B2 (ja) *	2019-03-15	2024-09-11	ノヴォノルディスクアー／エス	Ｇｌｐ－１ペプチドを噴霧乾燥するためのプロセス
WO2020190757A1 (en)	2019-03-15	2020-09-24	Novetide Ltd.	Improved processes for the preparation of semaglutide
CN111748019A (zh) *	2019-03-29	2020-10-09	深圳翰宇药业股份有限公司	一种多肽衍生化合物的合成方法
MA55504A (fr)	2019-04-01	2022-02-09	Novo Nordisk As	Anticorps dirigés contre le liraglutide et leur utilisation
CN112351994B (zh) *	2019-04-11	2024-06-07	江苏豪森药业集团有限公司	一种多受体激动剂及其医药用途
CN111909256A (zh) *	2019-05-10	2020-11-10	宁波鲲鹏生物科技有限公司	多肽衍生物及其制备方法
CA3139613A1 (en) *	2019-05-21	2020-11-26	Medimmune Limited	Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
HRP20251672T1 (hr)	2019-09-02	2026-02-13	Novo Nordisk A/S	Postupak proizvodnje tablete koja sdrži glp-1 peptide
US20230192799A1 (en) *	2019-09-16	2023-06-22	Biomarin Pharmaceutical Inc.	CNP Variants and Conjugates Thereof
CN110590934B (zh) *	2019-09-25	2020-12-08	北京乐普医药科技有限公司	一种glp-1化合物
IL291876A (en)	2019-11-06	2022-06-01	Novo Nordisk As	Receptor agonists in glp-1 type dementia
EP3819308A1 (en)	2019-11-07	2021-05-12	Fresenius Kabi iPSUM S.r.l.	Process for the manufacture of derivatized amino acids
WO2021089752A1 (en)	2019-11-07	2021-05-14	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021105393A1 (en)	2019-11-29	2021-06-03	Novo Nordisk A/S	Processes for obtaining stable glp-1 compositions
MX2022006861A (es)	2019-12-04	2022-07-11	Scripps Research Inst	Agonistas del receptor glp2 y metodos de uso.
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
EP4086277A4 (en) *	2019-12-30	2024-02-14	Gan & Lee Pharmaceuticals Co., Ltd.	Long-acting glp-1 compound
EP4085077A4 (en)	2019-12-31	2024-01-17	Beijing QL Biopharmaceutical Co., Ltd.	Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh)	2020-01-11	2022-06-14	北京质肽生物医药科技有限公司	Glp-1和fgf21的融合蛋白的缀合物
HRP20241159T1 (hr)	2020-02-07	2024-12-06	Gasherbrum Bio, Inc.	Heterociklički agonisti za glp-1
CN115484935A (zh)	2020-02-14	2022-12-16	G2G生物公司	包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
CN111253475B (zh) *	2020-02-18	2021-03-09	江苏诺泰澳赛诺生物制药股份有限公司	Glp-1激动多肽化合物及其盐与合成方法及用途
WO2021205388A2 (en)	2020-04-10	2021-10-14	Fresenius Kabi Oncology Limited	An improved process for the preparation of semaglutide side chain
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
CN115461044B (zh)	2020-04-29	2025-06-10	诺和诺德股份有限公司	包含glp-1激动剂和组氨酸的固体组合物
TW202206429A (zh)	2020-04-29	2022-02-16	美商迦舒布魯姆生物有限公司	雜環ｇｌｐ—１促效劑
AR122579A1 (es) *	2020-06-12	2022-09-21	Lilly Co Eli	Proceso para preparar un agonista dual glp-1 / glucagón
US20230346961A1 (en)	2020-07-22	2023-11-02	Novo Nordisk A/S	Glp-1 and gip receptor co-agonists
JP2023537501A (ja)	2020-08-06	2023-09-01	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環ｇｌｐ－１アゴニスト
JP2023538071A (ja)	2020-08-20	2023-09-06	アンブルックス，インコーポレイテッド	抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
EP4210680A1 (en)	2020-09-07	2023-07-19	Cyprumed GmbH	Improved pharmaceutical formulations of glp-1 receptor agonists
CN114729060B (zh) *	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
WO2022096636A1 (en)	2020-11-06	2022-05-12	Novo Nordisk A/S	Glp-1 prodrugs and uses hereof
TWI850611B (zh)	2020-12-18	2024-08-01	丹麥商諾佛儂迪克股份有限公司	Glp-1及澱粉素受體之共促效劑
WO2022199629A1 (zh)	2021-03-25	2022-09-29	博瑞生物医药（苏州）股份有限公司	Gip和glp-1的双受体激动剂、药物组合物及用途
CA3213805A1 (en)	2021-04-03	2022-10-06	Feng Tian	Anti-her2 antibody-drug conjugates and uses thereof
TW202304500A (zh)	2021-04-21	2023-02-01	瑞士商諾華公司	升糖素樣肽化合物
KR20240032010A (ko)	2021-06-09	2024-03-08	더 스크립스 리서치 인스티튜트	장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
CA3221661A1 (en)	2021-06-10	2022-12-15	Alexander HOVARD SPARRE-ULRICH	Treatment of obesity and obesity-related disorders
JP2024521399A (ja)	2021-06-10	2024-05-31	ニューレリス、インク．	小児患者における発作性障害を治療するための組成物および方法
KR102815534B1 (ko)	2021-06-23	2025-06-02	주식회사 펩트론	세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
CN117561072A (zh) *	2021-06-25	2024-02-13	甘李药业股份有限公司	含glp-1化合物的药物组合物
WO2022268214A1 (zh)	2021-06-25	2022-12-29	甘李药业股份有限公司	Pcsk9抑制剂和glp-1受体激动剂的药物组合
WO2023285334A1 (en)	2021-07-12	2023-01-19	Novo Nordisk A/S	Novel fatty acid modified urocortin 2 derivatives and the uses thereof
WO2023284822A1 (en)	2021-07-14	2023-01-19	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion polypeptides for metabolic disorders
EP4370102A1 (en)	2021-07-15	2024-05-22	Novo Nordisk A/S	Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN116554299A (zh) *	2021-07-19	2023-08-08	青岛博睿精创科技有限公司	长效glp-1多肽类似物及其制备方法和应用
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations
US20240374587A1 (en)	2021-09-08	2024-11-14	Shionogi & Co., Ltd.	Medicine for prevention and treatment of diseases linked to anti-obesity activity
AU2022386166A1 (en)	2021-11-10	2024-06-20	I2O Therapeutics, Inc.	Ionic liquid compositions
WO2023110833A1 (en)	2021-12-13	2023-06-22	Novo Nordisk A/S	Pharmaceutical formulations comprising a cyclodextrin
WO2023110758A1 (en)	2021-12-13	2023-06-22	Ascendis Pharma Growth Disorders A/S	Effective doses of cnp conjugates
JP2025509281A (ja)	2022-03-09	2025-04-11	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
US20250206757A1 (en)	2022-03-21	2025-06-26	Gasherbrum Bio, Inc.	5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4323413A4 (en)	2022-03-30	2025-10-15	Beijing Ql Biopharmaceutical Co Ltd	LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
WO2023187067A1 (en)	2022-03-30	2023-10-05	Novo Nordisk A/S	Formulation method
US20250250269A1 (en)	2022-04-14	2025-08-07	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
AR129270A1 (es)	2022-05-10	2024-08-07	Novo Nordisk As	Profármacos y usos de los mismos
EP4529454A1 (en)	2022-05-23	2025-04-02	Ascendis Pharma Growth Disorders A/S	Liquid pharmaceutical formulations of cnp compounds
CN119907661A (zh)	2022-07-05	2025-04-29	G2G生物公司	含有司美格鲁肽或其药学上可接受的盐的缓释微球制剂及其制备方法
WO2024068848A1 (en)	2022-09-28	2024-04-04	Zealand Pharma A/S	Methods for treating obesity
WO2024079043A1 (en)	2022-10-10	2024-04-18	Bachem Holding Ag	Method of manufacturing a peptide with a lysine derivative
WO2024104922A1 (en)	2022-11-14	2024-05-23	Ascendis Pharma Growth Disorders A/S	Method of improving skeletal muscle function
TW202421645A (zh)	2022-11-25	2024-06-01	丹麥商諾佛儂迪克股份有限公司	如ｇｌｐ—１之肽治療劑的口服投與
AU2023397760A1 (en)	2022-12-16	2025-06-26	Peptron, Inc.	Sustained-release microspheres including glp-1 receptor agonist or pharmaceutically acceptable salt thereof and use thereof
CN116159027A (zh) *	2022-12-29	2023-05-26	江苏诺泰澳赛诺生物制药股份有限公司	一种司美格鲁肽冻干药物组合物及其制备方法
JP2026502943A (ja)	2022-12-30	2026-01-27	アルギファルマエーエス	経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2024179606A1 (zh) *	2023-03-02	2024-09-06	甘李药业股份有限公司	一种glp-1化合物的医药用途
WO2024184351A1 (en)	2023-03-06	2024-09-12	Ascendis Pharma A/S	Compounds of drugs with an albumin binding moiety
JP2026509773A (ja)	2023-03-06	2026-03-25	アセンディスファーマエー／エス	アルブミン結合性部分を含む薬物化合物
EP4676535A1 (en)	2023-03-06	2026-01-14	Ascendis Pharma A/S	Multi-albumin binding compounds
AU2024240722A1 (en)	2023-03-20	2025-09-18	Ascendis Pharma Growth Disorders A/S	Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250167609A (ko)	2023-03-30	2025-12-01	노보 노르디스크 에이/에스	융합 화합물 및 그 용도
WO2024234320A1 (zh) *	2023-05-17	2024-11-21	南京知和医药科技有限公司	一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
KR20260022948A (ko)	2023-06-09	2026-02-20	썬 파마슈티컬 인더스트리스 리미티드	Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
KR20240176455A (ko)	2023-06-15	2024-12-24	노보 노르디스크 에이/에스	시클로덱스트린을 포함하는 약학적 제형
WO2025069009A1 (en)	2023-09-29	2025-04-03	Graviton Bioscience Bv	Rock2 inhibitors in the treatment of obesity
WO2025077751A1 (zh) *	2023-10-09	2025-04-17	甘李药业股份有限公司	Glp-1肽组合物及其用途
WO2025078040A1 (en)	2023-10-09	2025-04-17	Bachem Holding Ag	Lysine salt and method of manufacturing a lysine derivative
WO2025106773A1 (en)	2023-11-17	2025-05-22	Apnimed, Inc. (Delaware)	Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
TW202540155A (zh)	2023-11-30	2025-10-16	丹麥商諾佛儂迪克股份有限公司	Glp-1、gip及澱粉素受體之三重促效劑
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025169190A2 (en)	2024-02-06	2025-08-14	Opko Biologics Ltd.	Modified oxyntomodulin and methods of use thereof
EP4721761A1 (en)	2024-10-07	2026-04-08	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en)	2024-07-23	2026-01-28	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en)	2024-02-16	2025-08-20	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en)	2024-07-23	2026-01-28	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721760A1 (en)	2024-10-07	2026-04-08	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en)	2024-02-16	2025-08-20	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en)	2024-02-16	2025-08-21	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en)	2024-02-16	2025-08-21	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
GB202403746D0 (en)	2024-03-15	2024-05-01	New Roger Randal Charles	Formulations demonstrating an oral depot effect
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025231285A1 (en) *	2024-05-02	2025-11-06	Kallyope, Inc.	Peptide analogs and methods of using the same
WO2025248124A1 (en)	2024-05-31	2025-12-04	Zealand Pharma A/S	Dapiglutide for use in treating a sub-group of subjects
WO2026008836A1 (en)	2024-07-05	2026-01-08	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
WO2026013135A1 (en)	2024-07-10	2026-01-15	Ascendis Pharma A/S	Albumin-binding reagents
WO2026013138A1 (en)	2024-07-10	2026-01-15	Ascendis Pharma A/S	Compounds with improved albumin-binding
WO2026013136A1 (en)	2024-07-10	2026-01-15	Ascendis Pharma A/S	Albumin-binding compounds
WO2026073030A1 (en)	2024-09-27	2026-04-02	Carmot Therapeutics Inc.	Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists
DK182293B1 (en)	2025-01-16	2026-02-25	Novo Nordisk As	Semaglutide for use in medical therapy including weight management

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE193541T1 (de)	1989-03-20	2000-06-15	Gen Hospital Corp	Insulinotropes hormon
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5336782A (en)	1991-04-24	1994-08-09	Kuraray Co., Ltd.	Long chain carboxylic acid imide ester
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
IL128332A0 (en) *	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
EP0929576A1 (en)	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivatives
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
EP1056774A1 (en)	1998-02-27	2000-12-06	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
JP2002506792A (ja) *	1998-02-27	2002-03-05	ノボノルディスクアクティーゼルスカブ	Ｎ末端修飾ｇｌｐ−１誘導体
EP1060192A2 (en)	1998-02-27	2000-12-20	Novo Nordisk A/S	Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1061946B1 (en)	1998-02-27	2004-04-28	Novo Nordisk A/S	Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2003522099A (ja)	1998-02-27	2003-07-22	ノボノルディスクアクティーゼルスカブ	遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
CZ295044B6 (cs) *	1998-12-07	2005-05-18	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
BR0010750A (pt)	1999-05-17	2002-02-26	Conjuchem Inc	Peptìdeos insulinotrópicos de longa duração
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US20040001827A1 (en)	2002-06-28	2004-01-01	Dennis Mark S.	Serum albumin binding peptides for tumor targeting
WO2001051071A2 (en)	2000-01-11	2001-07-19	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
IL155812A0 (en)	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
FR2819810B1 (fr)	2001-01-23	2004-05-28	Pf Medicament	Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en)	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
EP1423136A4 (en)	2001-08-10	2007-07-25	Epix Pharm Inc	POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
AR036711A1 (es)	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
AU2003200839B2 (en)	2002-01-08	2008-12-11	Eli Lilly And Company	Extended glucagon-like peptide-1 analogs
AU2003278807A1 (en)	2002-03-01	2004-08-13	Bracco International B.V.	Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
CA2480858A1 (en)	2002-04-10	2003-10-23	Eli Lilly And Company	Treatment of gastroparesis
DE602004025205D1 (de)	2003-02-19	2010-03-11	Ipsen Pharma	Glp-1-analoga
JP2006520818A (ja)	2003-03-19	2006-09-14	イーライリリーアンドカンパニー	ポリエチレングリコール結合ｇｌｐ−１化合物
BRPI0409976A (pt) *	2003-05-09	2006-05-09	Novo Nordisk As	composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
WO2005014049A2 (en) *	2003-08-08	2005-02-17	Novo Nordisk A/S	Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
BR122019021416A2 (2) *	2003-09-19	2019-12-21
EP1667724A2 (en)	2003-09-19	2006-06-14	Novo Nordisk A/S	Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (ru)	2003-09-19	2010-10-10	Ново Нордиск А/С	Производные глюкагон-подобного пептида-1 (glp-1)
EP1696962A2 (en)	2003-12-18	2006-09-06	Novo Nordisk A/S	Novel glp-1 analogues linked to albumin-like agents
ATE461217T1 (de)	2003-12-18	2010-04-15	Novo Nordisk As	Glp-1-verbindungen
CA2572770A1 (en)	2004-07-08	2006-01-19	Novo-Nordisk A/S	Polypeptide protracting tags comprising a tetrazole moiety
WO2006037810A2 (en)	2004-10-07	2006-04-13	Novo Nordisk A/S	Protracted glp-1 compounds
MX2007005521A (es)	2004-11-12	2007-05-18	Novo Nordisk As	Formulaciones estables de peptidos insulinotropicos.
EP1863537A2 (en)	2005-03-18	2007-12-12	Novo Nordisk A/S	Dimeric peptide agonists of the glp-1 receptor
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
US8603972B2 (en)	2005-03-18	2013-12-10	Novo Nordisk A/S	Extended GLP-1 compounds

2006
- 2006-03-17 TW TW095109086A patent/TWI362392B/zh active
- 2006-03-17 TW TW098124221A patent/TWI372629B/zh active
- 2006-03-20 CN CN200680006674.6A patent/CN101133082B/zh not_active Expired - Lifetime
- 2006-03-20 DK DK06725149.6T patent/DK1863839T3/da active
- 2006-03-20 DE DE602006015928T patent/DE602006015928D1/de not_active Expired - Lifetime
- 2006-03-20 HU HUE10169546A patent/HUE028194T2/en unknown
- 2006-03-20 BR BRPI0607762A patent/BRPI0607762B8/pt active IP Right Grant
- 2006-03-20 EP EP06725149A patent/EP1863839B1/en not_active Expired - Lifetime
- 2006-03-20 US US11/908,834 patent/US8129343B2/en active Active
- 2006-03-20 WO PCT/EP2006/060855 patent/WO2006097537A2/en not_active Ceased
- 2006-03-20 CN CN201310534370.9A patent/CN104017062A/zh not_active Withdrawn
- 2006-03-20 RU RU2007134156A patent/RU2434019C3/ru active Protection Beyond IP Right Term
- 2006-03-20 ES ES06725149T patent/ES2350051T3/es not_active Expired - Lifetime
- 2006-03-20 PL PL10169546T patent/PL2322546T3/pl unknown
- 2006-03-20 CN CN201410513914.8A patent/CN104402989A/zh not_active Withdrawn
- 2006-03-20 EP EP10169546.8A patent/EP2322546B1/en not_active Expired - Lifetime
- 2006-03-20 PT PT101695468T patent/PT2322546E/pt unknown
- 2006-03-20 MX MX2007011220A patent/MX2007011220A/es active IP Right Grant
- 2006-03-20 KR KR1020077017241A patent/KR101205272B1/ko not_active Expired - Lifetime
- 2006-03-20 JP JP2008501334A patent/JP5209463B2/ja not_active Expired - Lifetime
- 2006-03-20 BR BR122019002626A patent/BR122019002626A2/pt not_active Application Discontinuation
- 2006-03-20 ES ES10169546.8T patent/ES2557313T3/es not_active Expired - Lifetime
- 2006-03-20 PL PL06725149T patent/PL1863839T3/pl unknown
- 2006-03-20 DK DK10169546.8T patent/DK2322546T3/en active
- 2006-03-20 CA CA2601784A patent/CA2601784C/en not_active Expired - Fee Related
- 2006-03-20 PT PT06725149T patent/PT1863839E/pt unknown
- 2006-03-20 AT AT06725149T patent/ATE476446T1/de active
- 2006-03-20 AU AU2006224536A patent/AU2006224536B9/en active Active
2007
- 2007-06-19 IL IL184051A patent/IL184051A/en active Protection Beyond IP Right Term
- 2007-08-28 ZA ZA200707261A patent/ZA200707261B/en unknown
- 2007-10-18 NO NO20075342A patent/NO337946B1/no active Protection Beyond IP Right Term
2010
- 2010-01-19 JP JP2010009025A patent/JP4585037B2/ja not_active Expired - Lifetime
2012
- 2012-03-05 US US13/412,283 patent/US8536122B2/en not_active Expired - Lifetime
- 2012-11-02 JP JP2012242654A patent/JP2013063984A/ja not_active Withdrawn
2018
- 2018-04-19 BE BE2018C016C patent/BE2018C016I2/fr unknown
- 2018-04-24 HU HUS1800019C patent/HUS1800019I1/hu unknown
- 2018-04-24 NL NL300936C patent/NL300936I2/nl unknown
- 2018-04-26 FR FR18C1017C patent/FR18C1017I2/fr active Active
- 2018-07-05 NO NO2018023C patent/NO2018023I1/no unknown

Also Published As

Publication number	Publication date
TWI372629B (en)	2012-09-21
BE2018C016I2 (2)	2025-09-05
DK2322546T3 (en)	2015-12-14
CN101133082B (zh)	2016-01-13
US8536122B2 (en)	2013-09-17
TWI362392B (en)	2012-04-21
NO2018023I1 (2)	2018-07-05
MX2007011220A (es)	2007-10-17
ATE476446T1 (de)	2010-08-15
CN104402989A (zh)	2015-03-11
US20090156478A1 (en)	2009-06-18
CA2601784C (en)	2013-12-24
PT2322546E (pt)	2016-01-22
PL2322546T3 (pl)	2016-03-31
RU2007134156A (ru)	2009-04-27
CN101133082A (zh)	2008-02-27
DK1863839T3 (da)	2010-11-22
US20120295847A1 (en)	2012-11-22
IL184051A (en)	2015-08-31
TW200700433A (en)	2007-01-01
AU2006224536A1 (en)	2006-09-21
US8129343B2 (en)	2012-03-06
PL1863839T3 (pl)	2011-01-31
DE602006015928D1 (de)	2010-09-16
WO2006097537A3 (en)	2007-01-25
JP2008533105A (ja)	2008-08-21
KR101205272B1 (ko)	2013-01-11
RU2434019C3 (ru)	2020-07-20
NO20075342L (no)	2007-12-18
PT1863839E (pt)	2010-11-10
BRPI0607762A2 (pt)	2010-03-23
NO337946B1 (no)	2016-07-18
NL300936I2 (nl)	2018-08-07
JP5209463B2 (ja)	2013-06-12
FR18C1017I1 (fr)	2018-06-15
FR18C1017I2 (fr)	2019-05-17
IL184051A0 (en)	2007-10-31
BRPI0607762B1 (pt)	2019-05-07
ES2350051T3 (es)	2011-01-17
EP1863839A2 (en)	2007-12-12
HUS1800019I1 (hu)	2018-06-28
JP2013063984A (ja)	2013-04-11
JP4585037B2 (ja)	2010-11-24
AU2006224536B9 (en)	2012-05-10
JP2010116407A (ja)	2010-05-27
CN104017062A (zh)	2014-09-03
HUE028194T2 (en)	2016-12-28
RU2434019C2 (ru)	2011-11-20
ES2557313T3 (es)	2016-01-25
EP2322546B1 (en)	2015-09-30
EP1863839B1 (en)	2010-08-04
EP2322546A1 (en)	2011-05-18
KR20070120089A (ko)	2007-12-21
WO2006097537A2 (en)	2006-09-21
ZA200707261B (en)	2008-05-28
AU2006224536B2 (en)	2012-04-05
BR122019002626A2 (2)	2019-04-02
TW200942255A (en)	2009-10-16
CA2601784A1 (en)	2006-09-21

Legal Events

Date	Code	Title	Description
2009-10-06	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.
2012-12-04	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2015-10-06	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-03-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2017-08-22	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2018-03-20	B15K	Others concerning applications: alteration of classification	Free format text: "PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07K 14/605 Ipc: C07K 14/605 (2006.01), A61K 38/00 (2006.01) Ipc: C07K 14/605 (2006.01), A61K 38/00 (2006.01) Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07K 14/605; A61K 38/26; A61K 47/48.
2018-11-13	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-03-26	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-05-07	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-12-28	B22O	Other matters related to patents and certificates of addition of invention: legal action concerning patent	Free format text: INPI NO 52402.012746/2021-70 ORIGEM: 14A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1086937-78.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM AUTOR: NOVO NORDISK A/S E NOVO NORDISK FARMACEUTICA DO BRASIL LTDA. REU(S): INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL
2025-09-02	B22O	Other matters related to patents and certificates of addition of invention: legal action concerning patent	Free format text: INPI NO 52402.011018/2025-74 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1031074-98.2025.4.01.3400 SUB JUDICE AUTOR: NOVO NORDISK A/S REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI

Publication	Publication Date	Title
BRPI0607762B8 (pt)	2021-05-25	análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto
UY27720A1 (es)	2003-10-31	Aroilpiridinonas monocíclicas,
UY29781A1 (es)	2007-04-30	Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CL2004001069A1 (es)	2005-04-01	Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
BRPI0615150A2 (pt)	2017-06-20	agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
AR047928A1 (es)	2006-03-01	Derivados de tetrahidropiridoindol
HN2003000196A (es)	2004-11-22	Derivados de indolinfenilsulfonamida
BRPI0517701A8 (pt)	2018-01-23	métodos de tratamento de diabetes mellitus
CL2012003281A1 (es)	2013-05-17	Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
UY27740A1 (es)	2003-10-31	Nuevos compuestos
BRPI0615157A2 (pt)	2016-09-13	composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
DK1797053T3 (da)	2011-02-21	Phenothiazinium-forbindelse til sårheling
ECSP056194A (es)	2006-04-19	Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
CL2010000188A1 (es)	2011-04-01	Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2007003000A1 (es)	2008-06-13	Compuestos derivados de biaril eter urea; composicion farmaceutica que los contienen; y su uso para el tratamiento de enfermedades o afecciones asociadas a la actividad de amida hidrolasa de acidos grasos (faah).
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CL2007001915A1 (es)	2008-01-18	Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
ES2422556T3 (es)	2013-09-12	Tratamiento de hepatitis vírica
SV2009003299A (es)	2009-12-14	Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CL2007002121A1 (es)	2008-02-22	Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2007001870A1 (es)	2008-06-13	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
CL2008002295A1 (es)	2009-03-27	Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008002430A1 (es)	2009-10-16	Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
PA8720801A1 (es)	2008-11-19	Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CL2008002162A1 (es)	2009-05-29	Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.